Literature DB >> 3308410

Optimum management of nausea and vomiting in cancer chemotherapy.

P L Triozzi1, J Laszlo.   

Abstract

Nausea and vomiting continue to be critical problems in cancer chemotherapy, although considerable progress has been made toward understanding the neuropharmacological mechanisms of vomiting and how chemotherapeutic agents and antiemetics affect these mechanisms. The principles of behavioural psychology have also been applied in an effort to understand and effectively manage these complications which have potentially serious consequences. For example, there is now some degree of rationality to our use of metoclopramide for cisplatin-induced nausea and vomiting, the use of combination antiemetic regimens, and use of lorazepam for the prevention (albeit unproven) of anticipatory nausea and vomiting. It must be admitted, however, that our approach is for the most part still empirical. Selecting an antiemetic programme is not a simple task. The emetogenic potential of the chemotherapy being used, the presence of coexisting diseases, the potential toxicity of the antiemetic drug and whether antiemetic therapy is to take place in the hospital or in an outpatient setting, the familiarity of the clinician with the various antiemetic therapies, and cost are all factors which need to be considered. Although phenothiazines remain the standard treatment, they are of little value against chemotherapy programmes that produce moderate or severe problems. Newer pharmacological approaches including butyrophenones, cannabinoids, metoclopramide, high-dose corticosteroids, and benzodiazepines have shown increased antiemetic efficacy, as have combinations of these agents which are directed against multiple sites of emetogenic activity. The role of behavioural therapies, which have been shown to be effective particularly in children and in anticipatory nausea and vomiting, needs to be more firmly established. Rather than recommending a given antiemetic programme for any particular chemotherapy, it is preferable to think in terms of initial approaches and how they can be modified. No one antiemetic programme is effective or safe in all situations.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3308410     DOI: 10.2165/00003495-198734010-00005

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  24 in total

1.  The gastrointestinal tract in chemotherapy-induced emesis. A final common pathway.

Authors:  O E Akwari
Journal:  Drugs       Date:  1983-02       Impact factor: 9.546

2.  Amitriptyline plus fluphenazine to prevent chemotherapy-induced emesis in cancer patients: a double-blind randomized cross-over study.

Authors:  W A Mellink; G H Blijham; W A van Deyk
Journal:  Eur J Cancer Clin Oncol       Date:  1984-09

3.  Lorazepam in cancer patients treated with cisplatin: a drug having antiemetic, amnesic, and anxiolytic effects.

Authors:  J Laszlo; R A Clark; D C Hanson; L Tyson; L Crumpler; R Gralla
Journal:  J Clin Oncol       Date:  1985-06       Impact factor: 44.544

4.  Optimizing metoclopramide control of cisplatin-induced emesis.

Authors:  B R Meyer; M Lewin; D E Drayer; M Pasmantier; L Lonski; M M Reidenberg
Journal:  Ann Intern Med       Date:  1984-03       Impact factor: 25.391

Review 5.  The clinical application of chronobiology to oncology.

Authors:  W J Hrushesky
Journal:  Am J Anat       Date:  1983-12

6.  A pilot investigation of the psychologic functioning of patients with anticipatory vomiting.

Authors:  E M Altmaier; W E Ross; K Moore
Journal:  Cancer       Date:  1982-01-01       Impact factor: 6.860

7.  The effect of administration rate on cisplatin-induced emesis.

Authors:  N S Jordan; P K Schauer; A Schauer; C Nightingale; G Golub; R S Martin; H M Williams
Journal:  J Clin Oncol       Date:  1985-04       Impact factor: 44.544

8.  High-dose intravenous metoclopramide versus combination high-dose metoclopramide and intravenous dexamethasone in preventing cisplatin-induced nausea and emesis: a single-blind crossover comparison of antiemetic efficacy.

Authors:  S B Strum; J E McDermed; D F Liponi
Journal:  J Clin Oncol       Date:  1985-02       Impact factor: 44.544

Review 9.  The control of chemotherapy-induced emesis.

Authors:  L J Seigel; D L Longo
Journal:  Ann Intern Med       Date:  1981-09       Impact factor: 25.391

10.  Combination antiemetic therapy in the control of chemotherapy-induced emesis.

Authors:  C L Fortner; R S Finley; W R Grove
Journal:  Drug Intell Clin Pharm       Date:  1985-01
View more
  15 in total

Review 1.  Pharmacokinetic optimisation of antiemetic therapy.

Authors:  M Campbell; D N Bateman
Journal:  Clin Pharmacokinet       Date:  1992-08       Impact factor: 6.447

Review 2.  Adverse effects of cancer chemotherapy. An overview of techniques for avoidance/minimisation.

Authors:  M Nicolson; R C Leonard
Journal:  Drug Saf       Date:  1992 Sep-Oct       Impact factor: 5.606

3.  Differential interactions of traditional and novel antiemetics with dopamine D2 and 5-hydroxytryptamine3 receptors.

Authors:  A Hamik; S J Peroutka
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

Review 4.  Clinical pharmacology and therapeutics.

Authors:  R C Horton; M J Kendall
Journal:  Postgrad Med J       Date:  1991-12       Impact factor: 2.401

Review 5.  Granisetron. A review of its pharmacological properties and therapeutic use as an antiemetic.

Authors:  G L Plosker; K L Goa
Journal:  Drugs       Date:  1991-11       Impact factor: 9.546

Review 6.  Pharmacological Agents Affecting Emesis : A Review (Part II).

Authors:  F Mitchelson
Journal:  Drugs       Date:  1992-04       Impact factor: 9.546

Review 7.  Ondansetron: a pharmacoeconomic and quality-of-life evaluation of its antiemetic activity in patients receiving cancer chemotherapy.

Authors:  G L Plosker; R J Milne
Journal:  Pharmacoeconomics       Date:  1992-10       Impact factor: 4.981

8.  Clinical management of dying patients.

Authors:  J Gavrin; C R Chapman
Journal:  West J Med       Date:  1995-09

Review 9.  Rational pharmacotherapy of gastrointestinal motility disorders.

Authors:  P Demol; H J Ruoff; T R Weihrauch
Journal:  Eur J Pediatr       Date:  1989-04       Impact factor: 3.183

10.  The antiemetic efficacy and safety of granisetron compared with metoclopramide plus dexamethasone in patients receiving fractionated chemotherapy over 5 days. The Granisetron Study Group.

Authors: 
Journal:  J Cancer Res Clin Oncol       Date:  1993       Impact factor: 4.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.